Plain-English translation of NCT04819841 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach called nula-cel for people with severe sickle cell disease. Researchers take your own blood stem cells, use a gene-editing tool called CRISPR to fix the genetic mutation that causes sickle cell disease, and then return the corrected cells to your body. The goal is to allow your body to produce healthy red blood cells and reduce the pain and complications of sickle cell disease.
Current treatments for severe sickle cell disease can help manage symptoms, but they don't cure the disease. This medication aims to offer a potential cure by fixing the root cause of the problem—the genetic mutation itself—rather than just treating the symptoms.
You likely qualify if…
You likely don't qualify if…
You would undergo chemotherapy to prepare your body to receive the corrected stem cells. Your own blood stem cells would be collected, edited in the laboratory to fix the sickle cell mutation, and then given back to you through an IV infusion. You would need to stay in the hospital during this process and have close medical monitoring as your immune system recovers and the new cells take hold in your bone marrow.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States